Long-Term Real-World Use of Cabotegravir and Rilpivirine Shows Sustained Efficacy in HIV Management

New real-world data from the OPERA study spanning five years confirms that the combination of cabotegravir and rilpivirine remains effective for maintaining viral suppression in people living with HIV. The findings, presented at IDWeek 2026, support its use as a long-acting injectable regimen despite challenges in adherence seen in clinical trials. Upcoming results from the CROWN study are expected to further validate these outcomes.

The OPERA study, presented at IDWeek 2026, provides five-year real-world evidence that the long-acting injectable regimen of cabotegravir and rilpivirine maintains sustained viral suppression in people living with HIV. This data comes from actual clinical use outside controlled trial environments, offering a more realistic assessment of treatment durability over time. While earlier clinical trials had noted adherence challenges—particularly around consistent injection schedules—the real-world findings suggest that despite these hurdles, the regimen remains effective for long-term management. The study’s extended duration underscores its potential as a viable alternative to daily oral antiretrovirals, especially for individuals seeking reduced medication burden.

The background for this development lies in the growing demand for long-acting HIV therapies that improve quality of life and reduce treatment fatigue. Previous trials had shown promise but raised concerns about adherence, which could compromise efficacy if injections were missed or delayed. The OPERA study’s real-world design helps address those concerns by reflecting actual patient behavior over time. The findings support ongoing efforts by healthcare providers and public health agencies to expand access to injectable regimens, particularly in populations where daily pill-taking is difficult due to stigma, lifestyle factors, or systemic barriers.

Key stakeholders include pharmaceutical companies developing long-act